Ferring Pharmaceuticals (Ferring) is a private, research-driven specialty biopharmaceutical company active in global markets.
The company identifies, develops and markets innovative products in the fields of endocrinology, gastroenterology, infertility, obstetrics, urology and osteoarthritis.
In recent years Ferring has expanded beyond its traditional European base: with over 5,000 employees worldwide, it operates subsidiaries in over 60 countries and makes its products available in more than 110 countries.
The company has emerged as a world leader in research with one of the largest peptide therapeutics portfolios in the industry.
As part of its commitment to developing innovative products to treat diseases with high unmet medical need, Ferring invests heavily in its research infrastructure both in terms of people and technology.
In addition to FRI, there are two other US based Ferring affiliates headquartered in Parsippany, New Jersey.
President of the Executive Board & Chief Operating Officer, Ferring Group
Mr. Michel Pettigrew joined Ferring in May 2001. He is the President of the Executive Board for the Ferring Group, and in addition, manages all Commercial, Global Marketing, Business Development, Product Supply, Research, Development and Regulatory activities of the company. He is also Chairman of Ferring Holding Inc, Ferring’s largest subsidiary.
Prior to his arrival at Ferring, Michel held several senior management positions throughout the world during a long career with Bristol-Myers Squibb.
Michel has a Bachelor of Commerce degree from McGill University in Montreal where he also plays an active role with the McGill Desautels Faculty of Management Alma Matter, and an MBA from York University in Toronto, Canada
Lars Peter Brunse
Executive Vice President and Chief Production Officer
Mr Lars Peter Brunse joined Ferring as Associate Director in 2000 and was shortly after promoted to Senior Vice President, Technical Operations and Logistics. He has led the expansion of Ferring’s manufacturing capability with the development of an additional nine state-of-the-art production sites, and extended the company’s product supply network from approximately 500 employees in the year 2000 to over 1,600 today. Prior to joining Ferring, Lars Peter worked at Novo Nordisk in Manufacturing, Operational Excellence, and Quality Assurance Management.
Lars Peter holds a Master degree in Pharmaceutical Sciences from University of Copenhagen.
Executive Vice President and Chief Medical Officer
Professor Klaus Dugi joined Ferring in October 2017. He is responsible for Global Medical Affairs, Quality Assurance and Pharmacovigilance.
Prior to joining Ferring, Klaus held various leadership roles at Boehringer Ingelheim, including Vice President Global Medical Affairs, Chief Medical Officer, and, most recently, Managing Director UK & Ireland.
A Professor of Medicine, with a specialty in Internal Medicine, Klaus continues to teach medicine at Heidelberg University, Germany. He also spent four years carrying out research at the US National Institutes of Health (NIH) and has published more than 70 manuscripts in peer-reviewed journals including The Lancet and Diabetes
Jean Duvall Group
Executive Vice President and Group General Counsel
Ms. Jean Duvall joined Ferring in November 2006 and is responsible for all legal activities on a global basis.
Prior to her arrival at Ferring, Jean was General Counsel at Elan Corporation, plc. She has a Bachelor of Science degree from Case Western Reserve University and a Juris Doctor degree from Ohio State University
Executive Vice President and Chief Scientific Officer
Dr. Per Falk is responsible for overseeing all of Ferring’s Research, Development & Regulatory activities.
Per’s career includes positions as Associate Professor/Lecturer at the Dept. of Medicine at the Karolinska Institute in Stockholm and adjunct Associate Professor at the Department of Molecular Biology and Pharmacology at Washington University School of Medicine in St. Louis. In 1998, he joined AstraZeneca where he served as Head of Gastrointestinal Pharmacology and Molecular Biology. Per joined Novo Nordisk in 2002 as VP of Experimental Medicine. From 2004, he served as VP for clinical development, medical affairs and regulatory affairs in Japan and US before returning to Denmark to serve as Senior Vice President Biopharmaceuticals Research.
Per trained and practiced medicine in Gothenburg and Stockholm and has a Ph.D. in Biochemistry from Gothenburg University.
Executive Vice President and Chief Financial Officer
Mr. Aaron Graff joined Ferring in 2002 as Vice President Global Marketing, Business Development, and Medical Affairs, based in Copenhagen, Denmark. After leading the acquisition and integration of Israeli biopharmaceutical company BTG in 2005, he relocated his team to the newly established Ferring International Center in Saint-Prex, Switzerland, where he was promoted to Senior Vice President, Asia Region and Global Marketing. Since 2010, Aaron has led Ferring’s U.S. operations from its U.S headquarters in New Jersey, first as Chief Operating Officer and since 2016 as Chief Executive Officer. Prior to joining Ferring, Aaron worked at Bristol-Myers Squibb for over 17 years.
Aaron has a Bachelor of Business Administration and Finance from University of Michigan, and an MBA from NYU Stern School of Business.
Executive Vice President and Chief Financial Officer
Mr. Dominic Moorhead joined Ferring in July 2017 as Chief Financial Officer (CFO).
Dominic has 30 years’ finance and business experience in the life sciences industry. For the past year, he has been a strategic advisor to executives and investors in biotech. Previously, he worked for Takeda Pharmaceuticals as Global Financial Controller, and CFO of the international business following the acquisition of Nycomed. Prior to this Dominic worked for Hoffmann-La Roche, where he was CFO of the Pharma Division for nine years during a period of transformation and growth. He was engaged in numerous strategic initiatives and business transactions, as well as their operational implications, culminating in the privatisation of Genentech in the U.S. in 2009.
Dominic has an ACA from Institute of Chartered Accountants in England and Wales and a BSc in Chemistry from the University of Nottingham.